Oridonin restores hepatic lipid homeostasis in an LXRα-ATGL/EPT1 axis-dependent manner
10.1016/j.jpha.2023.08.010
- Author:
Yulian CHEN
1
;
Huanguo JIANG
;
Zhikun ZHAN
;
Jindi LU
;
Tanwei GU
;
Ping YU
;
Weimin LIANG
;
Xi ZHANG
;
Shilong ZHONG
;
Lan TANG
Author Information
1. NMPA Key Laboratory for Research and Evaluation of Drug Metabolism,Guangdong Provincial Key Laboratory of New Drug Screening,School of Pharmaceutical Sciences,Southern Medical University,Guangzhou,510515,China
- Keywords:
Oridonin;
Lipid homeostasis;
TG reduction;
PE elevation;
LXRα-ATGL/EPT1 axis
- From:
Journal of Pharmaceutical Analysis
2023;13(11):1281-1295
- CountryChina
- Language:Chinese
-
Abstract:
Hepatosteatosis is characterized by abnormal accumulation of triglycerides(TG),leading to prolonged and chronic inflammatory infiltration.To date,there is still a lack of effective and economical therapies for hepatosteatosis.Oridonin(ORI)is a major bioactive component extracted from the traditional Chinese medicinal herb Rabdosia rubescens.In this paper,we showed that ORI exerted significant protective ef-fects against hepatic steatosis,inflammation and fibrosis,which was dependent on LXRα signaling.It is reported that LXRα regulated lipid homeostasis between triglyceride(TG)and phosphatidylethanol-amine(PE)by promoting ATCL and EPT1 expression.Therefore,we implemented the lipidomic strategy and luciferase reporter assay to verify that ORI contributed to the homeostasis of lipids via the regulation of the ATGL gene associated with TG hydrolysis and the EPT1 gene related to PE synthesis in a LXRα-dependent manner,and the results showed the TG reduction and PE elevation.In detail,hepatic TG overload and lipotoxicity were reversed after ORI treatment by modulating the ATCL and EPT1 genes,respectively.Taken together,the data provide mechanistic insights to explain the bioactivity of ORI in attenuating TG accumulation and cytotoxicity and introduce exciting opportunities for developing novel natural activators of the LXRα-ATGL/EPT1 axis for pharmacologically treating hepatosteatosis and metabolic disorders.
